Transient Osteoporosis of Pregnancy: A Possible Peptide Mediator
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Transient osteoporosis of pregnancy (TOoP) is uncommonly encountered in orthopedic and obstetric practice, with most reports consisting of single cases.
This rare condition consists of significant osteoporosis affecting the hips and spine, causing significant morbidity, and putting young female patients at risk for vertebral and femoral neck fractures.
The pathogenesis of transient osteoporosis of pregnancy is unknown, with various theories as to its etiology.
Recently, a number of reports have described elevated levels of PTHrP in patients with transient osteoporosis in pregnancy and of the postpartum period Our goal in this study is to assess the role of PTHrP in transient osteoporosis of pregnancy
| Condition |
|---|
|
Transient Osteperosis |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Female |
Inclusion Criteria:
- Signed Informed consent
Contacts and Locations| Principal Investigator: | Efrain Liebner, MD | Hadassah Medical Organization |
| Study Chair: | Meir Liebergall, M.D | Hadassah Medical Organization |
| Study Director: | Tzvi Bar-Shavit, Ph.D | The Hebrew University |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00541645 History of Changes |
| Other Study ID Numbers: | Lib001-HMO-CTIL |
| Study First Received: | October 7, 2007 |
| Last Updated: | March 17, 2008 |
| Health Authority: | Israel: Ministry of Health |
ClinicalTrials.gov processed this record on May 19, 2013